Latest Institutional Placements News

EcoGraf Limited (ASX:EGR) is raising approximately AUD 2 million through an underwritten Share Purchase Plan (SPP) offering new shares at a 20% discount. The funds will support key project financing and expansion activities at its Epanko Graphite Project and related operations.

Titomic has raised A$16.5 million through an institutional placement priced at a 23.5% discount, aiming to scale its Huntsville facility and accelerate US growth. The company also advanced a US$10 million loan application with the Export-Import Bank and appointed aerospace veteran Jim Chilton to its board.

Alliance Aviation Services has launched the retail tranche of its fully underwritten $40 million equity raising, offering shareholders new shares at $0.70 each to reinforce its balance sheet and support ongoing turnaround efforts.

GR Engineering Services launches a $10 million share purchase plan at the same price as a recent $100 million institutional placement, offering eligible shareholders a chance to invest up to $30,000 each.

Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.

L1 Gold Fund Limited (ASX:LGF) has launched a retail entitlement offer aiming to raise up to $261.7 million by issuing one new share for every three held, priced at $2.25 each. This follows a $254.9 million institutional placement and entitlement offer completed earlier in August.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Vection Technologies (ASX:VR1) achieved a major earnings inflection in FY26 with adjusted EBITDA soaring 596% to $3.8 million and generating positive operating cash flow for the first time, underpinned by dual commercial platforms scaling rapidly.

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.